How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) released its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.09. The biotechnology company earned $10.04 million during the quarter, compared to the consensus estimate of $8.83 million. Strongbridge Biopharma had a negative net margin of 115.67% and a negative trailing twelve-month return on equity of 66.82%.

What other stocks do shareholders of Strongbridge Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Energy Transfer (ET) , Selecta Biosciences (SELB) , Rigel Pharmaceuticals (RIGL) , Agile Therapeutics (AGRX) , Dicerna Pharmaceuticals (DRNA) , Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB) .

NASDAQ:SBBP

Strongbridge Biopharma (SBBP) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free SBBP Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.95
▼
$2.06
50-Day Range: $1.89
▼
$2.29
52-Week Range: $1.85
▼
$4.26

Volume: 684,684 shs
Average Volume: 866,464 shs
Market Capitalization: $135.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Strongbridge Biopharma alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Strongbridge Biopharma Stock (NASDAQ:SBBP)

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

SBBP Stock News Headlines

February 10, 2024 | investing.com

Matinas BioPharma Holdings Inc (MTNB)

November 15, 2023 | lse.co.uk

Lytix Biopharma As Share Price (LYTIX.OL)

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

November 4, 2023 | morningstar.com

Ambrx Biopharma Inc AMAM

August 19, 2023 | seekingalpha.com

HILS Hillstream BioPharma, Inc.

July 1, 2023 | finance.yahoo.com

ABUS - Arbutus Biopharma Corporation

April 25, 2023 | thestreet.com

The Nominees for Best Biopharma CEO of 2015 Are...

January 11, 2023 | marketwatch.com

Day One Biopharma Shares Rise 13% After Positive Topline Results for Tovorafenib

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

September 22, 2022 | markets.businessinsider.com

Accord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and Patients

September 23, 2021 | apnews.com

Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by ...

September 23, 2021 | finance.yahoo.com

Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.

September 14, 2021 | stockhouse.com

Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma

September 9, 2021 | apnews.com

Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris ...

August 31, 2021 | apnews.com

Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders ...

August 31, 2021 | finance.yahoo.com

Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

August 5, 2021 | sfgate.com

Strongbridge Biopharma: Q2 Earnings Snapshot

August 5, 2021 | finance.yahoo.com

Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 2, 2021 | finance.yahoo.com

Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement

July 29, 2021 | finance.yahoo.com

Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021

July 29, 2021 | finance.yahoo.com

Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue

July 28, 2021 | nasdaq.com

Strongbridge Biopharma's (NASDAQ:SBBP) Stock Price Has Reduced 48% In The Past Three Years

July 27, 2021 | finance.yahoo.com

Strongbridge Biopharma (SBBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

July 27, 2021 | apnews.com

Strongbridge Biopharma plc Announces Dates of Special Shareholder Meetings in Connection with ...

July 26, 2021 | msn.com

BRIEF-Strongbridge Biopharma Plc, Unit, Avenue Venture Opportunities Fund Enter Amendment To A Term Loan Agreement

See More Headlines

Receive SBBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/05/2021
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SBBP
CUSIP: N/A
CIK: 1634432
Web: www.strongbridgebio.com
Phone: (610) 254-9200
Fax: N/A
Employees: 72
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-45,080,000.00
Net Margins: -115.67%
Pretax Margin: N/A
Return on Equity: -66.82%
Return on Assets: -36.21%

Debt

Debt-to-Equity Ratio: 0.38
Current Ratio: 3.00
Quick Ratio: 2.95

Sales & Book Value

Annual Sales: $30.73 million
Price / Sales: 4.41
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.98 per share
Price / Book: 2.04

Miscellaneous

Outstanding Shares: 67,829,000
Free Float: N/A
Market Cap: $135.66 million
Optionable: Optionable
Beta: 1.58

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

John H. Johnson
Chief Executive Officer & Director
Richard S. Kollender
President & Chief Financial Officer
Fredric Cohen
Chief Medical Officer
Brian Conner
Chief Compliance Officer
Peter J. Valentinsson
Senior Vice President-Global Technical Operations

Key Competitors

View All Competitors

SBBP Stock Analysis - Frequently Asked Questions

How were Strongbridge Biopharma's earnings last quarter?: Strongbridge Biopharma plc (NASDAQ:SBBP) released its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.09. The biotechnology company earned $10.04 million during the quarter, compared to the consensus estimate of $8.83 million. Strongbridge Biopharma had a negative net margin of 115.67% and a negative trailing twelve-month return on equity of 66.82%.
What other stocks do shareholders of Strongbridge Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Energy Transfer (ET), Selecta Biosciences (SELB), Rigel Pharmaceuticals (RIGL), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB).

This page (NASDAQ:SBBP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Strongbridge Biopharma (SBBP) Stock Price, News & Analysis

About Strongbridge Biopharma Stock (NASDAQ:SBBP)

SBBP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

SBBP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info